论文部分内容阅读
目的 通过观察生脉注射液对恶性胸部肿瘤患者放疗后放射性肺炎、肺纤维化的临床疗效,探讨生脉注射液对放射性肺损伤的防治作用。方法 130例患者随机分为治疗组和对照组,对照组患者给予根治性放疗,治疗组患者给予根治性放疗加生脉注射液治疗,6 0ml加入5 %葡萄糖注射液2 5 0ml中,iv ,qd ,针对放疗中出现的不良反应给予相同的对症治疗,观察2组患者放射性肺炎和肺纤维化的发生率,以及生活质量评价。结果 治疗组放射性肺炎的发生率(12 .31% )与对照组(2 7.6 9% )相比有显著性差异(P <0 .0 5 ) ,治疗组肺纤维化发生率(33.85 % )与对照组(5 2 .31% )相比有显著性差异(P <0 .0 5 ) ,治疗组患者的生活质量评价明显高于对照组,与对照组相比有显著性差异(P <0 .0 1)。结论 中药制剂生脉注射液可以降低放疗后放射性肺炎及肺纤维化的发生率,对放射性肺损伤具有防治作用。
Objective To observe the clinical effects of Shengmai injection on radiation pneumonitis and pulmonary fibrosis after radiotherapy in patients with malignant thoracic tumors and to explore the preventive and therapeutic effects of Shengmai injection on radiation-induced lung injury. Methods 130 patients were randomly divided into treatment group and control group. Patients in control group were treated with radical radiotherapy. Patients in treatment group were treated with radical radiotherapy plus Shengmai injection. 60ml of dexamethasone was added into 250ml of 5% glucose injection. qd, given the same symptomatic treatment of adverse reactions in radiotherapy, the incidence of radiation pneumonitis and pulmonary fibrosis, and quality of life in two groups were observed. Results The incidence of radiation pneumonitis in treatment group (12.31%) was significantly different from that in control group (7.66%) (P 0. 05). The incidence of pulmonary fibrosis in treatment group (33.85%) was significantly correlated with (P <0.05), the quality of life of patients in the treatment group was significantly higher than that of the control group, there was significant difference (P <0) compared with the control group (P <0. 05) .0 1). Conclusion Shengmai injection can reduce the incidence of radiation pneumonitis and pulmonary fibrosis after radiotherapy, which has a preventive and therapeutic effect on radiation-induced lung injury.